Yahoo
BSE - Delayed Quote INR

Torrent Pharmaceuticals Limited (TORNTPHARM.BO)

4,635.15 +71.05 (+1.56%)
At close: October 30 at 3:28:50 PM GMT+5:30
Chart Range Bar
Loading chart for TORNTPHARM.BO
  • Previous Close 4,564.10
  • Open 4,559.15
  • Bid 4,615.05 x --
  • Ask 4,635.15 x --
  • Day's Range 4,559.15 - 4,668.55
  • 52 Week Range 2,891.45 - 4,668.55
  • Volume 62,448
  • Avg. Volume 6,064
  • Market Cap (intraday) 1.572T
  • Beta (5Y Monthly) 0.13
  • PE Ratio (TTM) 73.28
  • EPS (TTM) 63.25
  • Earnings Date Oct 23, 2026
  • Forward Dividend & Yield 32.00 (0.79%)
  • Ex-Dividend Date Jun 20, 2025
  • 1y Target Est 4,080.22

Torrent Pharmaceuticals Limited engages in the research, development, manufacturing, marketing, and distribution of branded and generic pharmaceutical formulations in India, the United States, Brazil, Germany, and internationally. The company offers products in various therapeutic areas, including anti-diabetic, anti-microbial, cardiovascular, urology, gynecology, oncology, gastro-intestinal, nephrology, neuro-psychiatric, cosmo-dermatology, pain management, anti-infective, and miscellaneous, as well as vitamins, minerals, and nutrients. It also provides contract manufacturing services. The company offers its products under Tedibar, Shelcal, Unienzyme, and Ahaglow brands. The company was formerly known as Trinity Laboratories and changed its name to Torrent Pharmaceuticals Limited in 1971. The company was founded in 1959 and is based in Ahmedabad, India. Torrent Pharmaceuticals Limited is a subsidiary of Torrent Investments Limited.

www.torrentpharma.com

17,059

Full Time Employees

March 31

Fiscal Year Ends

Healthcare

Sector

Recent News

View More

Earnings Trends

View More

Earnings Per Share

GAAP
Normalized
GAAP
Normalized

Revenue vs. Earnings

Annual
Quarterly
Annual
Quarterly
Q2 FY26
Revenue 33.02B
Earnings 5.91B
Profit Margin 17.90%

Q3

FY25

Q4

FY25

Q1

FY26

Q2

FY26

0
10B
20B
30B
17.0%
17.2%
17.4%
17.6%
17.8%

Analyst Insights

View More

Analyst Price Targets

3,530.00 Low
4,080.22 Average
4,635.15 Current
4,620.00

Analyst Recommendations

  • Strong Buy
  • Buy
  • Hold
  • Underperform
  • Sell

Statistics

View More

Valuation Measures

Annual
  • Market Cap

  • Enterprise Value

  • Trailing P/E

  • Forward P/E

  • PEG Ratio (current)

  • Price/Sales (ttm)

  • Price/Book (mrq)

  • Enterprise Value/Revenue

  • Enterprise Value/EBITDA

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    17.47%

  • Return on Assets (ttm)

    13.02%

  • Return on Equity (ttm)

    26.83%

  • Revenue (ttm)

    122.48B

  • Net Income Avi to Common (ttm)

    21.4B

  • Diluted EPS (ttm)

    63.25

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    7.94B

  • Total Debt/Equity (mrq)

    33.40%

  • Levered Free Cash Flow (ttm)

    9.87B

Company Insights

Research Reports

View More

People Also Watch

Mobilize your Website
View Site in Mobile | Classic
Share by: